140 related articles for article (PubMed ID: 38585879)
1. STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy.
Sheehy TL; Kwiatkowski AJ; Arora K; Kimmel BR; Schulman JA; Gibson-Corley K; Wilson JT
bioRxiv; 2024 Apr; ():. PubMed ID: 38585879
[TBL] [Abstract][Full Text] [Related]
2. Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy.
Nguyen DC; Song K; Jokonya S; Yazdani O; Sellers DL; Wang Y; Zakaria A; Pun SH; Stayton PS
ACS Cent Sci; 2024 Mar; 10(3):666-675. PubMed ID: 38559305
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
4. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.
Wilson J; Kimmel B; Arora K; Chada N; Bharti V; Kwiatkowski A; Finklestein J; Hanna A; Arner E; Sheehy T; Pastora L; Yang J; Pagendarm H; Stone P; Taylor B; Hubert L; Gibson-Corley K; May J; McLean J; Rathmell J; Richmond A; Rathmell W; Balko J; Fingleton B; Hargrove-Wiley E
Res Sq; 2024 May; ():. PubMed ID: 38766114
[TBL] [Abstract][Full Text] [Related]
5. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeted delivery of a STING agonist improvescancer immunotherapy.
Wu YT; Fang Y; Wei Q; Shi H; Tan H; Deng Y; Zeng Z; Qiu J; Chen C; Sun L; Chen ZJ
Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2214278119. PubMed ID: 36442099
[TBL] [Abstract][Full Text] [Related]
7. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells.
Wang L; Liang Z; Guo Y; Habimana JD; Ren Y; Amissah OB; Mukama O; Peng S; Ding X; Lv L; Li J; Chen M; Liu Z; Huang R; Zhang Y; Li Y; Li Z; Sun Y
Cell Death Dis; 2024 Apr; 15(4):265. PubMed ID: 38615022
[TBL] [Abstract][Full Text] [Related]
8. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
9. Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy.
Li Z; Zhang Q; Li Z; Ren L; Pan D; Gong Q; Gu Z; Cai H; Luo K
Acta Pharm Sin B; 2024 May; 14(5):2194-2209. PubMed ID: 38799622
[TBL] [Abstract][Full Text] [Related]
10. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
11. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
Xuan C; Hu R
ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
[TBL] [Abstract][Full Text] [Related]
12.
Chellen T; Bausart M; Maus P; Vanvarenberg K; Limaye N; Préat V; Malfanti A
Mater Today Bio; 2024 Jun; 26():101057. PubMed ID: 38660475
[TBL] [Abstract][Full Text] [Related]
13. Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists.
Pan X; Zhang W; Guo H; Wang L; Wu H; Ding L; Yang B
Biochem Pharmacol; 2023 Jul; 213():115596. PubMed ID: 37201875
[TBL] [Abstract][Full Text] [Related]
14. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
15. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
16. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
17. STING Agonists as Cancer Therapeutics.
Amouzegar A; Chelvanambi M; Filderman JN; Storkus WJ; Luke JJ
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070756
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway.
Cheng L; Zhang P; Liu Y; Liu Z; Tang J; Xu L; Liu J
Biomaterials; 2023 Oct; 301():122259. PubMed ID: 37531777
[TBL] [Abstract][Full Text] [Related]
19. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy.
Lu X; Miao L; Gao W; Chen Z; McHugh KJ; Sun Y; Tochka Z; Tomasic S; Sadtler K; Hyacinthe A; Huang Y; Graf T; Hu Q; Sarmadi M; Langer R; Anderson DG; Jaklenec A
Sci Transl Med; 2020 Aug; 12(556):. PubMed ID: 32801144
[TBL] [Abstract][Full Text] [Related]
20. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Hines JB; Kacew AJ; Sweis RF
Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
